Equity Overview
Price & Market Data
Price: $1.45
Daily Change: +$0.03 / 2.07%
Daily Range: $1.44 - $1.46
Market Cap: $6,449,118
Daily Volume: 5,645
Performance Metrics
1 Week: -37.72%
1 Month: -83.68%
3 Months: -70.84%
6 Months: -87.07%
1 Year: -91.84%
YTD: -68.43%
Company Details
Employees: 15
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.